GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (FRA:25I) » Definitions » Stock Based Compensation

ImmuPharma (FRA:25I) Stock Based Compensation : €0.11 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is ImmuPharma Stock Based Compensation?

ImmuPharma's Stock Based Compensation for the six months ended in Dec. 2024 was €0.07 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was €0.11 Mil.


ImmuPharma Stock Based Compensation Historical Data

The historical data trend for ImmuPharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Stock Based Compensation Chart

ImmuPharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.74 0.73 0.18 0.16 0.11

ImmuPharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 0.34 -0.17 0.04 0.07

ImmuPharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.11 Mil.


ImmuPharma Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of ImmuPharma's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuPharma Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.

ImmuPharma Headlines

No Headlines